Bills · HR 7050
IN COMMITTEE· 119TH CONGRESS
House BillHR 7050Health
Homeopathic Drug Product Safety, Quality, and Transparency Act
INTRO JAN 14· LAST ACTION JAN 14
READING
16MIN
COSPONSORS
6
READER REACTIONS0 TOTAL
NO VOTES YET · BE THE FIRST
- Introduced only
LEGISLATIVE PROGRESS
STEP 2 / 8Introduced
In Committee
Reported
Passed House
Passed Senate
Conference
To President
Became Law
WHAT THE BILL DOES
AI-writtenThis bill is important because it fundamentally changes how homeopathic products are controlled by the government. Currently, these products exist in a regulatory gray area, technically subject to the same strict FDA rules as conventional drugs, even though their unique nature makes applying those rules challenging. This has led to uncertainty for manufacturers and potential debates about consumer safety and product availability.
If this bill passes, it would establish a clear, dedicated regulatory path that acknowledges the unique characteristics of homeopathic remedies while still requiring adherence to established homeopathic standards for safety and quality. Without this bill, homeopathic products would likely continue to face regulatory ambiguities, potentially leading to increased scrutiny under conventional drug laws or limitations on their production and sale. It also introduces an accelerated approval process for manufacturers' requests, which could impact how quickly products come to market or adapt to new standards.
KEY PROVISIONS
5AI-extractedPROVISION 01
Establishes a distinct regulatory pathway for homeopathic drug products under the Federal Food, Drug, and Cosmetic Act.
This creates a separate legal framework for homeopathic products, distinguishing them from conventional drugs and potentially streamlining regulatory compliance.
PROVISION 02
Defines "homeopathic drug product" and "homeopathic ingredient" based primarily on recognized homeopathic pharmacopoeias and quality standards.
These definitions provide clarity on what products fall under this new regulatory pathway, reducing ambiguity for manufacturers and regulators.
PROVISION 03
Requires homeopathic drug products to comply with safety, quality, and manufacturing standards outlined in the Homeopathic Pharmacopoeia of the United States or other officially recognized homeopathic standards.
This ensures homeopathic products meet specific benchmarks for quality and safety that are tailored to their unique preparation methods.
PROVISION 04
Allows manufacturers to petition for exemptions or alternative manufacturing practices from good manufacturing practice regulations, with automatic approval if the Secretary fails to decide within 180 days, provided safety is not affected.
This provision offers flexibility for manufacturers and could speed up the adoption of new practices, but also places a time limit on regulatory review.
PROVISION 05
Excludes certain general drug provisions of the Federal Food, Drug, and Cosmetic Act from applying to homeopathic drug products if they conflict with the new specific requirements or established homeopathic standards.
This prevents conflicting regulatory standards from being applied, streamlining compliance for homeopathic products and clarifying their oversight.
SPONSORSHIP
1 + 6
R· Texas
YRS IN OFFICE
29
BILLS LED
21
COSPONSOR BREAKDOWNBIPARTISAN · 33%
DEM 1 REP 5 IND 0
ACTION TIMELINE
2 EVENTSJAN 14
Introduced in House
JAN 14
Referred to the House Committee on Energy and Commerce.
BILL INFO
TypeHouse Bill
NumberHR 7050
Congress119th
StatusIn Committee
IntroducedJan 14, 2026
Last actionJan 14, 2026
READER REACTIONS
OVERALL SENTIMENT
No reactions yet. Be the first to weigh in.
Discussion
Loading comments...
IN COMMITTEE· 119TH CONGRESS · ENERGY AND COMMERCE COMMITTEE · INTRODUCED JAN 14, 2026
House BillHR 7050Health
Homeopathic Drug Product Safety, Quality, and Transparency Act
INTRODUCED JAN 14, 2026· LAST ACTION JAN 14, 2026
PASSAGE CHANCES
—%
READING
16 min
COSPONSORS
6
COMPLEXITY
Moderate
